ClinicalTrials.gg
CompletedNCT03440164Updated Feb 22, 2018

Superior Silybin Bioavailability in Healthy Volunteers

An observational study in Liver Diseases and Chronic Liver Disease, sponsored by Medica Sur Clinic & Foundation. Completed. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-22.

Sponsored by Medica Sur Clinic & Foundation · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
24
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Twenty-four healthy volunteers of both genders, aged 18 to 44 years old and body mass indexes between 18 to 27 kg/m2,were selected to participate in a two-way, balanced, prospective, blind, single-dose crossover study with a one-week wash-out period. It was assessed that volunteers were free from significant cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal and hematological diseases. The volunteers clinical evaluation were determined by clinical examination, ECG, and the following laboratory tests: blood glucose, urea, creatinine, AST, ALT, GGT, alkaline phosphatase, total bilirubin and fractions, uric acid, total cholesterol, triglycerides, albumin and total protein, and routine urinalysis. All subjects were negative for HIV, HBV, and HCV.

Read the detailed description

In healthy volunteers single-dose crossover study with a one week, It was assessed that volunteers were free from significant cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal and hematological diseases. The volunteers clinical evaluation were determined by clinical examination

02

Conditions studied

  • Liver Diseases
  • Chronic Liver Disease

Keywords

  • liver fibrosis
  • Hepatoprotective
  • Sylimarin
03

In context

Liver Diseases

824 studies on the registry are indexed under Liver Diseases; 152 are open to participants now.

This study's enrollment of 24 is below the median of 200 across 262 observational studies indexed under Liver Diseases.

Browse Liver Diseases studies →

Lead sponsor

Medica Sur Clinic & Foundation is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All healthy volunteers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • volunteers were free from significant cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal and hematological diseases.

The volunteers clinical evaluation were determined by clinical examination, , and the following laboratory tests: blood glucose, urea, creatinine, , ALT, GGT, alkaline phosphatase, total and fractions, uric acid, total cholesterol, triglycerides, albumin and total protein, and routine urinalysis

Exclusion criteria

Exclusion Criteria:

  • Subject with , ,
  • Subject with comorbidities
  • Subject less 18 years old Subject higher 50 years old
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
24 participants (actual)
Patient registry
No

Interventions

  • OtherSylimarin and Sylibin

    We compared the plasma levels of Silibinin after a dosage of Silibinin-phosphatidylcholine complex, equivalent to 45 mg Silybin oily-medium soft-gel capsules after the conventional 70-mg Silymarin tablets, in 23 healthy volunteers

06

What researchers measure

Primary outcomes

  1. Time of the Bioavailability of the Silibinin vs Sylimarin

    Analysis of the Bioavailability

    Time frame: One week

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Mendez-Sanchez N, Dibildox-Martinez M, Sosa-Noguera J, Sanchez-Medal R, Flores-Murrieta FJ. Superior silybin bioavailability of silybin-phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers. BMC Pharmacol Toxicol. 2019 Jan 11;20(1):5. doi: 10.1186/s40360-018-0280-8. Erratum In: BMC Pharmacol Toxicol. 2019 Feb 22;20(1):14. doi: 10.1186/s40360-019-0290-1. BMC Pharmacol Toxicol. 2021 Jun 25;22(1):37. doi: 10.1186/s40360-021-00500-2. PubMed 30635055 ↗

Individual participant data

Plan to share: Yes — Our results will be published in a scientific journal

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: From 2017 to date

Access criteria: Publication in Open Acess

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2016 to primary completion in Dec 2016, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2018
First posted
Feb 22, 2018
StartActual
Nov 11, 2016
Primary completionActual
Dec 8, 2016
CompletionActual
Dec 15, 2016
Last update
Feb 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03440164
Lead sponsor
Medica Sur Clinic & Foundation
Responsible party
Nahum Méndez-Sánchez (Gastroenterologist and Hepatologist, Medica Sur Clinic & Foundation) — Principal investigator
First posted
Feb 22, 2018
Start date
Nov 11, 2016
Primary completion
Dec 8, 2016
Completion
Dec 15, 2016
Last update
Feb 22, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion